Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions

British Journal of Ophthalmology

Volumn 92, Issue 6, 2008, Pages 864-865

  Nigam, N ^a   Hedaya, J ^a   Freeman, W R ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB;

FLUORESCENCE ANGIOGRAPHY; HUMAN; LETTER; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; STANDARD; SUBRETINAL NEOVASCULARIZATION; TREATMENT INDICATION; TREATMENT OUTCOME; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DATA INTERPRETATION, STATISTICAL; HUMANS; TREATMENT FAILURE; VISUAL ACUITY;

EID: 45249098482     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.129296     Document Type: Letter

References (4)

1. Lux A, Llacer H, Heussen FM, Joussen AM. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007;91:1318-22.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
3. Freeman WR, Falkenstein I. Avastin and new treatments for AMD: where are we? Retina 2006;26:853-8.
4. Falkenstein IA, Cheng L, Morrison VL, et al. Standardized visual acuity results associated with primary versus secondary bevacizumab (Avastin) treatment for choroidal neovascularization in age-related macular degeneration. Retina 2007;27:701-6.